Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates ...

Two phase III studies of setrusumab, Orbit and Cosmic, for treating brittle bones have failed and left the developers ...

The development of new orthobiologic treatments and the smooth integration of AI are top accomplishments for these two orthopedic surgeons. Michael Stone, MD, and Bob Yin, MD, recently connected with ...